Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18K Sell
1,749
-11,467
-87% -$86.6K ﹤0.01% 7197
2026
Q1
$64.8K Buy
+13,216
New +$71.9K ﹤0.01% 5576
2025
Q2
– Sell
-17,107
Closed -$88K – 8692
2025
Q1
$96K Buy
17,107
+12,538
+274% +$102K ﹤0.01% 5093
2024
Q4
$39K Sell
4,569
-18,269
-80% -$108K ﹤0.01% 6108
2024
Q3
$158K Buy
22,838
+17,837
+357% +$111K ﹤0.01% 4755
2024
Q2
$31K Buy
+5,001
New +$37.5K ﹤0.01% 6523

Other funds holding CADL

Simplex Trading's CADL Position: Q2 2026 in Review

Simplex Trading reduced its Candel Therapeutics (CADL) stake by 87% in Q2 2026, selling an estimated $86.6K and leaving 1,749 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #7197.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 6 quarters since. The position peaked at $158K in Q3 2024. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Simplex Trading held 1,749 shares of Candel Therapeutics worth $18K as of Q2 2026.
  • Simplex Trading sold 11,467 Candel Therapeutics shares in Q2 2026, an estimated $86.6K.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7197 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.